A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs INCB 053914 (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Incyte Corporation
- 12 Dec 2017 Results (n=39; data cut off: 14 April 2017) assessing preliminary safety, pharmacokinetics and pharmacodynamics from part 1, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 16 May 2017 Planned number of patients changed from 135 to 270.
- 16 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History